세계의 동물용 백신 시장 : 제품 유형, 동물 유형, 질환 유형, 투여 경로, 유통 채널별 - 예측(2025-2030년)

The Animal Vaccines Market was valued at USD 13.69 billion in 2024 and is projected to grow to USD 14.58 billion in 2025, with a CAGR of 6.75%, reaching USD 20.27 billion by 2030.

In recent years, the animal vaccines market has emerged as a critical segment within the global health landscape, driven by growing awareness of animal health, food security, and public safety. This report provides an in-depth exploration of the evolving trends, technological advancements, and strategic imperatives that are reshaping this sector. The dynamic interplay between science, regulation, and market demand is creating opportunities and challenges that require a keen understanding of product innovations and host biology. This introduction sets the stage by outlining key themes including the role of novel vaccine development, the importance of robust clinical data, and the regulatory shifts that influence market adoption. The ongoing improvements in vaccine delivery methods and formulation techniques signify a transformative period that is redefining how veterinarians and livestock managers approach preventive animal health care. As we delve further into this comprehensive analysis, the discussion will illuminate both current practices and future growth prospects, thereby enabling decision-makers to align their strategies with emerging market signals.

The global animal vaccines landscape is characterized by ever-increasing research and development activities, integration of advanced biotechnologies, and strategic collaborations. These trends are not only fostering innovation but are also expanding the breadth of available vaccine products. As stakeholders navigate through regulatory complexities and competitive pressures, understanding these shifts becomes critical for aligning investment and operational priorities with long-term market realities.

Transformative Shifts in Market Dynamics

The animal vaccines market is currently experiencing transformative shifts that are reshaping industry dynamics and redefining competitive landscapes. Emerging technologies have paved the way for agile manufacturing processes and have significantly reduced the time-to-market for novel vaccine candidates. With pivotal advancements in genetic engineering and biotechnology, there is a marked transition from traditional vaccine formulations to innovative approaches such as mRNA and recombinant vaccines. This transformation is not solely driven by scientific breakthroughs but is also influenced by evolving regulatory frameworks that emphasize efficacy, safety, and rapid deployment in response to disease outbreaks.

A notable shift is occurring in the investment patterns, where increased funding in research and development is enabling a more personalized approach to animal immunization. Industry stakeholders are now leveraging data analytics and cutting-edge diagnostic tools to assess the unique disease profiles of different animal species, leading to more targeted vaccine solutions. Furthermore, the integration of digital health platforms has enhanced the ability to monitor post-vaccination outcomes, ensuring that real-world efficacy supports clinical trial claims. This digital transition is creating an environment where continuous feedback and adaptive manufacturing become the norm, thereby supporting a more resilient and responsive supply chain.

The emphasis on collaborative ventures between research institutions, biopharmaceutical companies, and veterinary practitioners has also intensified. Such alliances are critical in harnessing collective expertise to translate science into viable market solutions. Ultimately, the shift towards a more technologically empowered and data-informed industry underscores the potential for improved animal health outcomes, risk minimization, and a more sustainable vaccine market in the long run.

Key Segmentation Insights in Animal Vaccines

A detailed analysis of the animal vaccines market reveals multiple segmentation strategies that provide a rich understanding of the sector's diversity and depth. The product segmentation is particularly noteworthy as it encompasses a broad spectrum including inactivated vaccines, live attenuated vaccines, mRNA vaccines, recombinant vaccines, and subunit vaccines. These classifications illustrate the technological advancements and complex manufacturing processes designed to optimize immune responses across various species. This diversification in product profile enables stakeholders to address specialised needs and tailor solutions that align with distinct animal health challenges.

Moreover, segmentation based on animal type further refines market insights. The market distinguishes between companion animals and livestock, where the former, represented mainly by cats and dogs, and the latter, including cattle, poultry, sheep, and swine, drive distinct demand patterns and regulatory requirements. Such segmentation accounts for the variability in vaccine administration protocols and the differing economic considerations that underpin each segment. For instance, while companion animal vaccines are often driven by pet owner preferences and preventive health measures, vaccines for livestock animals must align with stringent food safety standards and biosecurity regulations.

The segmentation based on disease types adds another layer of granularity by focusing on bacterial infections, fungal infections, parasitic infections, and viral infections. Within this framework, bacterial infections are further divided into clostridial, Escherichia coli, leptospirosis, and pasteurella, while parasitic infections differentiate between ectoparasites and endoparasites. The viral segment covers several critical pathogens including avian influenza, bovine viral diarrhea virus, foot-and-mouth disease virus, Newcastle disease virus, porcine reproductive and respiratory syndrome virus, and rabies virus. These detailed sub-categories illustrate how the interplay between specific pathogens and vaccine responses drives innovation and market segmentation in clinical, logistical, and financial realms.

Additionally, analysis of the route of administration offers insights into the practical implications of vaccine design. The classifications include injectable and oral vaccines, with injectable routes being further delineated into intramuscular, intravenous, and subcutaneous methods. This detailed breakdown emphasizes how the route of administration can influence vaccine efficacy, compliance, and overall market penetration. Finally, the distribution channel segmentation, which includes online pharmacies, retail pharmacies, and veterinary clinics, underlines the market's adaptation to digital transformation while maintaining traditional physical distribution networks. Together, these segmentation strategies provide a comprehensive framework to understand market trends and enable stakeholders to craft strategies that effectively address the heterogeneous needs of diverse animal species and disease profiles.

Based on Product, market is studied across Inactivated Vaccines, Live Attenuated Vaccines, mRNA Vaccines, Recombinant Vaccines, and Subunit Vaccines.

Based on Animal Type, market is studied across Companion Animals and Livestock Animals. The Companion Animals is further studied across Cats and Dogs. The Livestock Animals is further studied across Cattle, Poultry, Sheep, and Swine.

Based on Disease Type, market is studied across Bacterial Infections, Fungal Infections, Parasitic Infections, and Viral Infections. The Bacterial Infections is further studied across Clostridial, E. Coli, Leptospirosis, and Pasteurella. The Parasitic Infections is further studied across Ectoparasites and Endoparasites. The Viral Infections is further studied across Avian Influenza Virus, Bovine Viral Diarrhea Virus (BVDV), Foot-and-Mouth Disease Virus (FMDV), Newcastle Disease Virus, Porcine Reproductive & Respiratory Syndrome Virus (PRRSV), and Rabies Virus.

Based on Route of Administration, market is studied across Injectable Vaccines and Oral Vaccines. The Injectable Vaccines is further studied across Intramuscular (IM), Intravenous (IV), and Subcutaneous (SC).

Based on Distribution Channel, market is studied across Online Pharmacies, Retail Pharmacies, and Veterinary Clinics.

Key Global Regional Insights

The regional landscape of the animal vaccines market is marked by distinct geographic trends that reflect variations in economic development, regulatory environments, and consumer preferences. The Americas remain a robust market characterized by high investment in advanced biotechnologies and a proactive approach to animal health. Nations in this region have embraced innovation through substantial funding and supportive governmental policies, which in turn have fostered a dynamic environment for vaccine research and development.

In Europe, the Middle East, and Africa, there is an increasing focus on integrating modern manufacturing techniques with traditional vaccination approaches. This region is witnessing a blend of mature markets with emerging economies where modernization is gradually expanding the scope of animal health initiatives. Stakeholders are focusing on strengthening supply chains, establishing quality control measures, and leveraging regional partnerships to improve access to state-of-the-art vaccine products. These efforts are particularly significant in light of rising concerns around zoonotic diseases and the imperative for stringent health monitoring of livestock populations.

Asia-Pacific represents a rapidly evolving market driven by population growth, urbanization, and rising incomes. This region has seen a surge in demand for advanced vaccines, primarily driven by the expanding livestock sector and the growing popularity of companion animals. Significant investments in research and a burgeoning biopharmaceutical industry are fueling the adoption of innovative vaccine technologies. The interplay between traditional agricultural practices and modern health management strategies in this region is not only boosting vaccine uptake but is also creating new opportunities for market entrants. The regional analysis highlights variations in regulatory frameworks and investment trends, which underscore the importance of tailoring strategic initiatives to local contexts for sustained market growth.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New Jersey, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insights on Strategic Key Companies in the Sector

The competitive landscape in the animal vaccines market is defined by the contributions of several leading companies that are actively shaping trends through innovation and strategic collaborations. Prominent industry players such as Biogenesis Bago S.A. and BioVaxys Technology Corporation have carved out significant market positions by focusing on research-driven approaches and comprehensive solutions that cater to both companion and livestock animal segments. Companies like Boehringer Ingelheim International GmbH and Brilliant Bio Pharma Private Limited continue to define the cutting edge of clinical development with their robust portfolio of vaccine offerings.

Other influential organizations, including Ceva Sante Animale and China Animal Husbandry Industry Co., Ltd., have made substantial inroads in emerging markets by leveraging local expertise and agile manufacturing processes. Dalan Animal Health and Elanco Animal Health Inc. further exemplify the trend towards integrated solutions that merge innovative vaccine technologies with efficient distribution networks. Additionally, firms such as Endovac Animal Health LLC by Immvac Inc. and Hester Biosciences Limited are pushing the boundaries by harnessing novel biotechnology platforms to address emerging pathogens.

Companies like HIPRA, S.A. and Indian Immunologicals Limited are playing pivotal roles in expanding market reach and enhancing vaccine efficacy through targeted research initiatives. The strategic moves from Kemin Industries, Inc. and Merck KGaA have underscored the importance of global partnerships, while Neogen Corporation and Phibro Animal Health Corporation have further expanded their influence through targeted acquisitions and market-specific adaptations. SAN Vet Holding GmbH, Sanofi S.A., and Seppic S.A. stand out for their commitment to continuous innovation, even as Torigen Pharmaceuticals Inc., Vaxxinova GmbH, and VEROVACCiNES GmbH consolidate their presence through specialized product lines. These trends are complemented by the focused efforts of Vetigenics LLC, Vetoquinol SA, Virbac, Inc., and Zoetis Inc., whose diverse strategies emphasize targeted research, agile manufacturing, and an unwavering commitment to improving animal health on a global scale. Their contributions not only drive market innovation but also emphasize a commitment to quality, efficacy, and global health standards.

The report delves into recent significant developments in the Animal Vaccines Market, highlighting leading vendors and their innovative profiles. These include Biogenesis Bago S.A., BioVaxys Technology Corporation, Boehringer Ingelheim International GmbH, Brilliant Bio Pharma Private limited, Ceva Sante Animale, China Animal Husbandry Industry Co., Ltd., Dalan Animal Health, Elanco Animal Health Inc., Endovac Animal Health, LLC by Immvac Inc., Hester Biosciences Limited, HIPRA, S.A., Indian Immunologicals Limited, Kemin Industries, Inc., Merck KGaA, Neogen Corporation, Phibro Animal Health Corporation, SAN Vet Holding GmbH, Sanofi S.A., Seppic S.A., Torigen Pharmaceuticals Inc., Vaxxinova GmbH, VEROVACCiNES GmbH, Vetigenics, LLC, Vetoquinol SA, Virbac, Inc., and Zoetis Inc.. Actionable Recommendations for Industry Leaders

For industry leaders operating in the animal vaccines market, several actionable recommendations are emerging from this comprehensive analysis. First, it is imperative to invest strategically in research and development initiatives that embrace novel vaccine technologies such as mRNA and recombinant platforms. Emphasizing collaborative studies with research institutions and leveraging digital health solutions can streamline development timelines and enhance vaccine efficacy. Capitalizing on data analytics to monitor post-market performance will also support targeted improvements in existing formulations.

Furthermore, strategic portfolio diversification across various product types addresses the distinct needs of both companion and livestock animals. Companies should consider integrating product development strategies that align with comprehensive disease coverage, ranging from bacterial to viral infections. Such diversification not only mitigates risk but also offers new revenue streams by addressing niche market demands.

Enhancing the efficiency of vaccine delivery channels is another key recommendation. Whether deploying injectable vaccines across intramuscular, intravenous, and subcutaneous routes or optimizing oral vaccine formulations, focusing on logistical and clinical efficiencies remains critical. In addition, refining distribution strategies across online platforms, retail pharmacies, and veterinary clinics can improve market penetration and consumer accessibility.

Finally, maintain adaptable regulatory and market strategies that respond dynamically to global trends. This includes proactive engagement with regulatory authorities to ensure alignment with evolving standards, especially in regions with rapidly changing market conditions. By fostering strategic alliances and pursuing regional customization of products and services, industry leaders can better position their organizations to capitalize on emerging opportunities and navigate the complexities of a dynamic global marketplace.

Conclusion and Future Outlook

In conclusion, the animal vaccines market is undergoing a period of significant transformation that is being shaped by technological innovation, strategic segmentation, and dynamic regional factors. This evolving landscape presents both challenges and opportunities that require industry stakeholders to be agile, forward-thinking, and committed to continuous improvement. The in-depth analysis presented herein highlights the importance of embracing novel vaccine platforms and integrating nuanced insights from product, animal type, and disease segmentation to create targeted, effective solutions.

Looking forward, the drive towards digital health integration, coupled with an increased focus on regulatory compliance and strategic global partnerships, will define the pathway for sustained growth and innovation. The synthesis of these industry trends not only affirms the critical role of animal vaccines in achieving improved animal health outcomes but also underscores the broader implications for food safety, public health, and economic development. As decision-makers recalibrate their strategies, the insights provided in this report offer a robust foundation for navigating a complex but promising market landscape.

The future of animal vaccines is bright, bolstered by continuous advancements in technology and science. Stakeholders must remain vigilant and responsive to emerging trends, ensuring that their strategic initiatives are backed by rigorous research and a deep understanding of regional market dynamics. This commitment to adaptive and innovative practices will be the key to unlocking new opportunities and sustaining long-term success in the animal vaccines sector.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of zoonotic diseases worldwide
    • 5.1.1.2. Government initiatives promoting animal health care globally
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with the R&D and production of animal vaccines
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging partnerships with wildlife conservation organizations
    • 5.1.3.2. Innovations in vaccine delivery methods enhancing administration and improving animal immune responses
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulations and approval processes associated with animal vaccines
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Increasing preference for attenuated live vaccines to protect against diseases with complex pathogen biology
  • 5.2.2. Animal Type: Rising significance of animal vaccines for companion animals owing to increasing pet ownership
  • 5.2.3. Disease Type: Increasing need for animal vaccines to deal with viral infections
  • 5.2.4. Route of Administration: Rising importance of IM vaccines owing to their quick absorption into the bloodstream
  • 5.2.5. Distribution Channel: Increasing preference for online pharmacies owing to growing adoption of digital platforms and convenience
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Animal Vaccines Market, by Product

• 6.1. Introduction
• 6.2. Inactivated Vaccines
• 6.3. Live Attenuated Vaccines
• 6.4. mRNA Vaccines
• 6.5. Recombinant Vaccines
• 6.6. Subunit Vaccines

7. Animal Vaccines Market, by Animal Type

• 7.1. Introduction
• 7.2. Companion Animals
  • 7.2.1. Cats
  • 7.2.2. Dogs
• 7.3. Livestock Animals
  • 7.3.1. Cattle
  • 7.3.2. Poultry
  • 7.3.3. Sheep
  • 7.3.4. Swine

8. Animal Vaccines Market, by Disease Type

• 8.1. Introduction
• 8.2. Bacterial Infections
  • 8.2.1. Clostridial
  • 8.2.2. E. Coli
  • 8.2.3. Leptospirosis
  • 8.2.4. Pasteurella
• 8.3. Fungal Infections
• 8.4. Parasitic Infections
  • 8.4.1. Ectoparasites
  • 8.4.2. Endoparasites
• 8.5. Viral Infections
  • 8.5.1. Avian Influenza Virus
  • 8.5.2. Bovine Viral Diarrhea Virus (BVDV)
  • 8.5.3. Foot-and-Mouth Disease Virus (FMDV)
  • 8.5.4. Newcastle Disease Virus
  • 8.5.5. Porcine Reproductive & Respiratory Syndrome Virus (PRRSV)
  • 8.5.6. Rabies Virus

9. Animal Vaccines Market, by Route of Administration

• 9.1. Introduction
• 9.2. Injectable Vaccines
  • 9.2.1. Intramuscular (IM)
  • 9.2.2. Intravenous (IV)
  • 9.2.3. Subcutaneous (SC)
• 9.3. Oral Vaccines

10. Animal Vaccines Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Online Pharmacies
• 10.3. Retail Pharmacies
• 10.4. Veterinary Clinics

11. Americas Animal Vaccines Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Animal Vaccines Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Animal Vaccines Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Anivive secures USD 20 million investment from Leonid Capital Partners to develop the next generation of pet health
  • 14.3.2. Boehringer Ingelheim unveils next-gen vaccine in India, tackling rising Marek's disease challenges
  • 14.3.3. BioVaxys and SpayVac expand vaccine production to advance wildlife contraception and aquaculture solutions
  • 14.3.4. Ceva Animal Health expands vaccine production with new Hungarian facility
  • 14.3.5. Merck Animal Health unveils RNA-particle feline vaccine to target feline leukemia virus
  • 14.3.6. Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio
  • 14.3.7. University of Missouri's innovative vaccine offers new hope against bovine anaplasmosis
  • 14.3.8. ICAR-CIBA and Indian Immunologicals Limited entered into an agreement for commercial development of fish vaccine
  • 14.3.9. Fischer MV partners with BAV to launch livestock and aquaculture vaccines in India
  • 14.3.10. Merck Animal Health's strategic acquisition of Elanco's aqua business enhances vaccine and treatment portfolio in aquaculture sector
  • 14.3.11. Huvepharma's EUR 72 million investment in Bulgarian veterinary vaccine plant to enhance global supply chain
  • 14.3.12. Pioneering partnership enhances African swine fever vaccine development for global pig protection
  • 14.3.13. Zoetis invests AUD 350 million to amplify vaccine production in Australia, bolstering animal health and industry collaboration
  • 14.3.14. Virbac's strategic acquisition of Sasaeah boosts its market position and innovation in Japan's animal vaccine market
  • 14.3.15. Zendal and CSIC introduce innovative DNA vaccine to combat leishmaniasis
• 14.4. Strategy Analysis & Recommendation
  • 14.4.1. Virbac, Inc.
  • 14.4.2. Phibro Animal Health Corporation
  • 14.4.3. Ceva Sante Animale
  • 14.4.4. Boehringer Ingelheim International GmbH

Companies Mentioned

• 1. Biogenesis Bago S.A.
• 2. BioVaxys Technology Corporation
• 3. Boehringer Ingelheim International GmbH
• 4. Brilliant Bio Pharma Private limited
• 5. Ceva Sante Animale
• 6. China Animal Husbandry Industry Co., Ltd.
• 7. Dalan Animal Health
• 8. Elanco Animal Health Inc.
• 9. Endovac Animal Health, LLC by Immvac Inc.
• 10. Hester Biosciences Limited
• 11. HIPRA, S.A.
• 12. Indian Immunologicals Limited
• 13. Kemin Industries, Inc.
• 14. Merck KGaA
• 15. Neogen Corporation
• 16. Phibro Animal Health Corporation
• 17. SAN Vet Holding GmbH
• 18. Sanofi S.A.
• 19. Seppic S.A.
• 20. Torigen Pharmaceuticals Inc.
• 21. Vaxxinova GmbH
• 22. VEROVACCiNES GmbH
• 23. Vetigenics, LLC
• 24. Vetoquinol SA
• 25. Virbac, Inc.
• 26. Zoetis Inc.